After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year

Pfizer says it has enough promising data on its respiratory syncytial virus, or RSV, vaccine designed to protect newborns that it will end enrollment in the study and submit for US Food and Drug Administration approval by the end of the year.